Scallop plasmalogens
Scallop-derived Purified Plasmalogens · also known as Plasmalogens, Scallop plasmalogens, Plasmalogens, Vinyl ether glycerophospholipids
Scallop plasmalogens have shown signs of antioxidant and neuroprotective activity in chemical and animal studies. The human trials on cognition are exploratory and in limited populations, so plasmalogens cannot be considered a proven treatment for mild cognitive impairment.
Clinical uses and human evidence
Memory
Studies (2)
- Fukuchi 2026 · Front Nutr · RCT · n=68 — Orally administered scallop-derived plasmalogens improve cognitive function in healthy middle-aged and older adults: a randomized, double-blind, placebo-controlled trial
- Fujino 2017 · EBioMedicine · RCT · n=328 — Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Attention and focus
Studies (2)
- Fukuchi 2026 · Front Nutr · RCT · n=68 — Orally administered scallop-derived plasmalogens improve cognitive function in healthy middle-aged and older adults: a randomized, double-blind, placebo-controlled trial
- Fujino 2022 · Front Cell Dev Biol · RCT · n=40 — Orally Administered Plasmalogens Alleviate Negative Mood States and Enhance Mental Concentration: A Randomized, Double-Blind, Placebo-Controlled Trial
Fatigue and energy
Age-related cognitive decline
Mechanisms of action
Neurotrophic factor synthesis and TrkB/A receptor activation
In mice, dietary plasmalogens can increase BDNF signaling in the hippocampus, and the related effects weakened when BDNF or TrkB was knocked down. In a 12-week human randomized trial, plasma BDNF did not differ significantly between groups, so the evidence for this neurotrophic pathway in humans is still limited.
Direct free radical trapping and chemical quenching
The vinyl ether bond of plasmalogens can react with oxidants or free radicals, and it acts as a sacrificial protector in chemical and membrane models. Whether it directly traps free radicals in humans, and whether 1–2 mg/day can achieve this in the brain, is currently unclear.
mTORC1 allosteric inhibition and macroautophagy induction
Changes in amyloid pathology were seen in animal models, but this does not show that mTOR is inhibited or that lysosomal autophagy clears more β-amyloid. There are currently no reliable studies showing that routine oral scallop plasmalogens induce autophagy in humans.